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Oxyntomodulin (OXM) is a peptide isolated from porcine intestine which consists of the whole glucagon 
sequence with a basic octapeptide (KA,) at its C-terminal end. In this study, the effect of OXM and KAB 
on pentagastrin-stimulated gastric acid secretion has been studied in conscious rats and cats. In rats, OXM 
(25-450 pmol . kg-‘) as well as KA, (7.5-40 nmol ’ kg-l) inhibited ~ntagast~n-stimulate gastric acid out- 
put in a dose-dependent manner; KA, was about IOO-times less potent than OXM. In cats, KA, (90 
nmol . kg-‘) was also an inhibitor of acid secretion. We conclude that OXM, or a closely related peptide, 
could be a physiological modulator of gastric acid secretion, and that the C-terminal octapeptide of OXM 
is implicated in this effect. 
Uxyntomod~ii~ Rat Cat 
1. INTRODUCTION 
Oxyntomodulin [l] is a peptide isolated from 
porcine jejuno-ileum, which consists of the whole 
glucagon sequence with a basic octapeptide at its 
C-terminal end [2]. The comparison between the 
biological activities of glucagon and oxyn- 
tomodulin has shown that ox~tomodulin (OXM) 
(25-250 pmol + kg-‘) is IO-20-times more potent 
than glucagon in inhibiting pentagastrin (PG)- 
stimulated gastric acid secretion in the anaesthe- 
tised rat [3]. This observation suggests that OXM 
may be a physiological modulator of gastric acid 
secretion and that the C-terminal octapeptide 
(RAs) which differentiates OXM from glucagon 
may be implicated in the biological activity of 
OXM. 
To examine these points, KAs has been syn- 
thesized, and both OXM and KAs have been ex- 
amined for their ability to interfere with PG- 
stimulated acid secretion in conscious rats, an 
animal whose secretion is under vagal and 
Acid secretion 
splanchnic control. The effect of K&I on acid 
secretion has also been studied in the cat. It has 
been found that both OXM and KAs inhibit PG- 
stimulated acid secretion, OXM being about a 
loo-times more potent than KAs in the rat. 
2. MATERIALS AND METHODS 
The octapeptide, KAs (Lys-Arg-Asn-Lys-Asn- 
Asn-Ile-Ala-OH), was synthesized by stepwise 
acylations in ‘liquid phase’ with active esters. The 
methods of synthesis used have been described in 
detail [4f. The benzyloxy~arbonyl group was used 
for the protection of the N, amino group, the tert- 
butyloxycarbonyl group for protection of the side 
chains of lysine, and the tert-butyl ester for protec- 
tion of the C-terminal alanine. Arginine was in- 
troduced as its tribenzyloxycarbonyl derivative and 
then left unprotected. The last lysine was coupled 
as its bisterbutyloxy~arbonyl active ester 
derivative. Final deprotection of the peptide was 
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performed with trifluoroacetic acid. The purity of 
the complete unprotected peptide was checked by 
high-performance liquid chromatography bBond- 
apak Cl8 column). The octapeptide was identified 
by elemental analysis, amino acid analysis and by 
its ‘H NMR spectrum (360 MHz). 
2.2. Experiments in conscious rats 
Wistar rats (IFFA CREDO, France) (300 g) pro- 
vided with a chronic gastric fistula [5], were condi- 
tioned to stay 5 h in Bollman-type cages. Tests 
began 14 days after implantation of the cannula. 
The animals were starved for 18 h before the ex- 
periment with free access to tap water. The gastric 
juice was collected by gravity-drainage through the 
fistula over 20-min periods. Fractions were 
weighed and analysed for acid concentration by 
titration with 0.01 N NaOH using 1% 
phenolphthalein as an indicator. Acid output was 
calculated by multiplying the volume of secretion 
by the acid concentration. Saline and pentagastrin 
(Peptavlon, ICI) (0.5 pug. kg-’ . h-‘) were ad- 
ministered as intravenous infusions at a rate of 
2 ml/h through silastic (Dow Corning) tubing. 
OXM and KAs were dissolved in a sterile 
physiological saline solution containing bovine 
serum albumin (fraction V, Sigma, O.SOro) and in- 
jected as a bolus in a 400 ~1 volume. Natural oxyn- 
tomodulin [I] extracted from pig intestine was us- 
ed. It contained no contaminants when analysed 
by high-performance liquid chromatography. The 
statistical probabilities were calculated by the Stu- 
dent’s t-test. 
2.3. Experiments in conscious cats 
Three adult cats (body wt 3.5-4.5 kg) were pro- 
vided with a gastric fistula 12-18 months before 
these experiments. Before each test, food, but not 
water, was withheld for 18 h. The interval between 
tests was at least 1 week, all tests were done in a 
random order. Throughout the experiments, saline 
was infused intravenously at a rate of 12 ml/h. 
The gastric juice was collected in 15min periods 
and acid output was calculated from determina- 
tions of HCl concentration (titration end point 7.8) 
and volumes. Basal secretion was studied for at 
least 30 min and stimulated secretion for 3 h. KAs 
was given as a bolus injection on the plateau PG 
secretion. Statistical probabilities were calculated 
by the Student’s t-test. 
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3. RESULTS 
3.1. Experiments in conscious rats 
Under basal conditions, the volume of gastric 
juice collected during 20 min was 507 f 77 ~1, the 
acid concentration was 70 + 9 meq/l, corre- 
sponding to an acid output of 37 + 5 req/20 
min (n = 7). Under stimulation by PC (0.5 
pg.kg-’ -h-l), the volume and the acid concentra- 
tion doubled and the resulting acid output tripled. 
The PC effect corresponded to 65-70% of the 
maximal acid secretory response. 
Natural porcine OXM (225 pmol/kg), when 
bolus injected, decreased both the volume of the 
gastric juice and the acid concentration, resulting 
in a decrease in the output of acid (fig.1). Inhibi- 
tion of PC&stimulated acid output attained about 
40% and was observed over 3 consecutive 20-min 
collection periods. Comparable effects were 
observed with synthetic KAs (fig.2), albeit with a 
higher dose (30 nmol/kg). 
The acid secretion induced by PC during 
120 min was calculated; the inhibition of this 
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Fig.1. Effect of a bolus injection of OXM on PG- 
stimulated gastric acid secretion in conscious rats 
provided with chronic gastric fistula. Data from OXM- 
injected rats (0) are expressed relatively to the plateau 
of stimulation obtained with perfusion of PG alone (0). 
Basal values (without PC) were deduced from each 
experimental point. Results are given as mean + SE, n = 
7. The statistical significance was performed against the 
control obtained at the same time. (a) p < 0.05, (b) p < 
0.002. 
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Fig.2. Effect of the C-terminal octapeptide (KAg) of 
porcine OXM on the PC&stimulated acid output in 
conscious rat. PG (a), mean * SE of 7 experiments; PG 
plus KA8 (0), mean f SE of 7 experiments; (b) p < 
0.002. 
secretion as a function of increasing doses of OXM 
and KAs is shown in fig.3. KAs was 133-times less 
potent than OXM in inhibiting gastric acid 
secretion. 
3.2. Experiments in conscious cats 
When the acid secretion of conscious cats was 
submaximally stimulated by PG (70% of the max- 
imal response), the synthetic octapeptide KAs 
(90 nmol/kg) inhibited gastric acid secretion: 
45-50070 inhibition was attained over 3 consecutive 
15-min periods (fig.4). 
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Fig.3. Effect of OXM or its C-terminal octapeptide 
(KA8) on PG (0.5 pg. kg-’ . h-‘) stimulated acid output 
as a function of the dose in conscious rat. Number of 
experiments in parentheses. 
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Fig.4. Effect of the C-terminal octapeptide (KA8) of 
porcine OXM on PO-stimulated acid output in 
conscious cat. PG (o), mean + SE of 6 experiments; PG 
plus K&J (0), mean + SE of 6 experiments; (b) p < 
0.002. 
4. DISCUSSION 
The jejuno-ileum and the endocrine pancreas of 
the rat contain large quantities of OXM [6]. In the 
rat, the presence of OXM in plasma was clearly 
shown [6]. OXM or molecules derived therefrom 
could be released under physiological cir- 
cumstances and regulate gastric functions. Our 
results confirm that OXM inhibits PG-stimulated 
gastric acid secretion and indicate that the vagal 
tone is compatible with this inhibitory effect. Fur- 
thermore, they indicate that KAs, the synthetic 
replica of the C-terminal octapeptide that differen- 
tiates OXM from glucagon can also inhibit acid 
secretion although being 1 OO- 150-times less potent 
than OXM. This is also the case in the cat. Recent- 
ly, molecular cloning techniques have allowed the 
characterization of the OXM sequence in rat and 
man [7,8]. In these species, an arginine residue 
replaces the lysine present in position 4 of porcine 
KAs (position 33 in OXM). The sequence of cat 
OXM is unknown. According to our data, it would 
appear that the structural differences between the 
OXM of mammals have little functional impor- 
tance, if any. 
As far as the mode of action of OXM and KAs 
is concerned, OXM is lo-20-fold less potent than 
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glucagon in its interaction with glucagon receptors 
in liver [2], adipose tissue (unpublished) and heart. 
In contrast, a receptor which preferentially binds 
OXM has been described in the rat fundic glands 
[9]; these glands also display a cyclic AMP system 
which is more sensitive to OXM than to glucagon 
[lo]. The similar specificities exhibited by the 
OXM binding sites [9], the oxyntic glands cyclic 
AMP system [IO] and the inhibition of gastric acid 
secretion, suggest hat these functional entities are 
related. However, the precise biochemical events 
which link the binding sites with the biological ac- 
tivity and the role of cyclic AMP in this process re- 
main unknown. 
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